Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5‐HT2) receptor
Open Access
- 1 February 1984
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 27 (2), 139-146
- https://doi.org/10.1002/art.1780270204
Abstract
Ketanserin, a selective antagonist of the 5-HT2 receptor, was evaluated in a 4-week open pilot trial of 30 patients with Raynaud's phenomenon. Moderate or marked relief was reported in 15 of 18 (83%) patients with systemic sclerosis, whereas only 4 of 12 (33%) patients with Raynaud's phenomenon of other etiology received such benefit (P < 0.01). These subjective ratings were supported by the results of serial digital strain gauge plethysmography during controlled cold challenge. Additional clinical findings suggested that ketanserin therapy facilitated the healing of ischemic digital ulcerations and reduced hand edema in patients with systemic sclerosis. These findings lend support to the hypothesis that serotonin is an important element in the pathogenesis of systemic sclerosis.This publication has 35 references indexed in Scilit:
- Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's PhenomenonNew England Journal of Medicine, 1983
- Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonistInflammation Research, 1982
- Abnormalities of Pulmonary Vascular Dynamics and Inflammation In Early Progressive Systemic SclerosisArthritis & Rheumatism, 1981
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Vasodilator Drugs in Peripheral Vascular DiseaseNew England Journal of Medicine, 1979
- 5-Hydroxytryptamine: A Cytospecific Growth Stimulator of Cultured FibroblastsScience, 1970
- Urinary 5-hydroxyindoleacetic Acid Excretion in Scleroderma**From the Division of Dermatology, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California.Journal of Investigative Dermatology, 1963
- Elimination of the Possibility of Glycogen Interference in the Glucose Oxidase Determination of Glucose**From the Division of Dermatology, University of Minnesota Hospitals, Minneapolis 14, Minnesota.Journal of Investigative Dermatology, 1963
- Response To Serotonin and Its Antagonists in Patients With Rheumatoid Arthritis and Related Diseases*†Angiology, 1959